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Molecular genetic testing for the 11p15-associated imprinting disorders Silver–Russell and Beckwith–Wiedemann syndrome
(SRS, BWS) is challenging because of the molecular heterogeneity and complexity of the affected imprinted regions. With the
growing knowledge on the molecular basis of these disorders and the demand for molecular testing, it turned out that there is an
urgent need for a standardized molecular diagnostic testing and reporting strategy. Based on the results from the ﬁrst external
pilot quality assessment schemes organized by the European Molecular Quality Network (EMQN) in 2014 and in context with
activities of the European Network of Imprinting Disorders (EUCID.net) towards a consensus in diagnostics and management of
SRS and BWS, best practice guidelines have now been developed. Members of institutions working in the ﬁeld of SRS and BWS
diagnostics were invited to comment, and in the light of their feedback amendments were made. The ﬁnal document was ratiﬁed
in the course of an EMQN best practice guideline meeting and is in accordance with the general SRS and BWS consensus
guidelines, which are in preparation. These guidelines are based on the knowledge acquired from peer-reviewed and published
data, as well as observations of the authors in their practice. However, these guidelines can only provide a snapshot of current
knowledge at the time of manuscript submission and readers are advised to keep up with the literature.
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CLINICAL BACKGROUND
Silver–Russell syndrome
Silver–Russell syndrome (Russell–Silver syndrome; SRS; OMIM
180860) is mainly deﬁned by severe intrauterine and postnatal growth
restriction (oP3) associated with a variable spectrum of further
features (for a review see Saal1). The typical SRS phenotype includes a
relative macrocephaly, a triangular-shaped face with a prominent
forehead, body and limb asymmetry, and feeding difﬁculties (for a
review see Azzi et al2 and Wakeling et al3). Some patients show a mild
motor and cognitive developmental delay, including learning
difﬁculties and speech delay.3,4 Furthermore, adult follow-up data
indicate an increased risk for metabolic disorders in later life.5
The clinical presentation is variable and probably partly inﬂuenced
by the mosaic distribution of molecular changes.6 Although several
scoring systems have been suggested (for a review see Azzi et al7), the
clinical diagnosis of SRS is difﬁcult because of its molecular and
clinical heterogeneity (Tables 1 and 2). Therefore, molecular testing is
often applied to patients who do not fulﬁll the strict clinical criteria,
resulting in a detection rate lower compared with that expected from
studies based on clinically well-deﬁned cohorts.8
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Beckwith–Wiedemann syndrome
Beckwith–Wiedemann syndrome (BWS; OMIM1306509) was initially
called EMG syndrome from its three main features exomphalos/
umbilical hernia, macroglossia and (neonatal) gigantism. Additional
signs include neonatal hypoglycemia, hemihypertrophy, organomegaly
(essentially kidney, liver, spleen, pancreas), earlobe creases, polyhy-
dramnios, hemangioma and cardiomyopathy. In 5–7% of children,
embryonal tumors (most commonly Wilm's tumor (WT)) are
diagnosed (for a review see Brioude et al10). The clinical diagnosis
of BWS is often difﬁcult because of its variable presentation and
overlap with other overgrowth syndromes (for a review see Shuman
et al11), and hence several scoring systems have been suggested12,13
(reviewed by Ibrahim et al14). Robust genotype/epigenotype–pheno-
type correlations have been established10,14–16 (Table 1): hemihyper-
trophy is strongly associated with upd(11)pat, exomphalos with H19/
IGF2:IG-DMR hypermethylation and CDKN1C mutations, and, most
importantly, the risk for WT is predominant in H19/IGF2:IG-DMR
hypermethylation and upd(11)pat. By contrast, other embryonal
tumors such as hepatoblastoma, neuroblastoma and adrenal tumors
are observed in patients with KCNQ1OT1:TSS-DMR or upd(11)pat,
although at a much lower incidence. In patients with a mosaic paternal
uniparental diploidy (also named 'genome-wide UPD'), further
tumors can occur, with a later age of onset than in case of the other
molecular subtypes. Hence, the determination of the molecular
subtype is important for an individual prognosis and management.
Nevertheless, phenotypic transitions are ﬂuid, ranging from some
features that include ‘incomplete BWS’ to the full clinical picture.
Thus, molecular testing for BWS is also suggested in case of isolated
hemihypertrophy as molecular changes in 11p15.5 have also been
identiﬁed in patients with isolated body asymmetry. It should
furthermore be considered in bilateral WT, familial WT cases and
WT patients with at least one feature of BWS.
Table 1 Molecular subtypes and their frequencies in the 11p15.5-associated imprinting disorders (frequencies of molecular subtypes
are taken from refs 1,6,9)
Chromosome Type of mutations/epimutation Frequency MLID
Mosaicism
possible Recurrence risk
SRS (OMIM 180860)1,6
11p15.5 H19/IGF2:IG-DMR hypomethylation 40–60% 7–10% Yes Empirically low, only in rare cases increased due to genomic
trans-acting mutations (eg, MLID)
Duplications/deletions o1% No No Up to 50%, depending on the gene content of the aberration
and the sex of the parent contributing the affected allele. In
case of duplication of the whole 11p15 region, SRS in case
of a maternal and BWS in case of a paternal transmission.
UPD 1 case — Yes Empirically low
CDKN1C point mutation 1 family No No 0% or 50%, depending on the sex of the parent contributing
the affected allele
IGF2 point mutation 1 family No No 0 or 50%, depending on the sex of the parent contributing
the affected allele
7 upd(7)mat 4–10% No No Empirically low, but some may be high because of familial
translocations
upd(7q)mat Single cases No No Empirically low
Duplications/deletions/translocations
affecting 7p13 and 7q32
Single cases No No Up to 50%
14q32 upd(14)mat, epimutation, duplications Single cases Unknown yes Refer to TS14 literature
Whole genome (Mosaic) maternal unidiploidy Single cases Yes No
(submicroscopic) chromosomal
imbalances
~1% No No Up 50%, depending on the chromosome and type of
rearrangement
BWS (OMIM130650)9
11p15.5 KCNQ1OT1:TSS-DMR hypomethylation 50–60% 25% Yes Empirically low, only in some cases increased because of
genomic trans-acting mutations (eg, MLID)
H19/IGF2:IG-DMR hypermethylation 5–10% No Yes 20% of patients carry OCT4/SOX2 binding site mutations or
deletions within the ICR1. In general, the recurrence risk is
empirically low, but if an underlying genetic defect is present
it may be up to 50%, depending on the gender of the
contributing carrier
upd(11)pat 20–25% No Yes Empirically low, but some may be high due to translocations
Duplications/deletions/(translocations) 1–2% No No Up to 50%, depending on the gene content of the aberration
and the sex of the parent contributing the affected allele. In
case of duplication of the whole 11p15 region, SRS in case
of a maternal and BWS in case of a paternal transmission
CDKN1C mutations 5% (sporadic)
50% (familial)
No No 0% or 50%, depending on the sex of the parent contributing
the affected allele
Whole genome (Mosaic) paternal unidiploidy ~1%? Yes No
Abbreviations: BWS, Beckwith–Wiedemann syndrome; MLID, multilocus imprinting disturbance; SRS, Silver–Russell syndrome.
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THE CHROMOSOMAL REGION 11P15.5
One of the major imprinted regions in humans is localized to the short
arm of chromosome 11 (11p15.5) (Figure 1). Several of the 11p15
genes are involved in human growth and development, as well as in
tumorigenesis. As a result, SRS and BWS, as the two imprinting
disorders (IDs) associated with 11p15.5 alterations, are clinically
characterized by disturbed growth and, in the case of BWS, associated
with an increased risk for tumors.
The chromosomal region 11p15.5 spans ~ 1 Mb and harbors two
separate imprinting control regions (ICRs): the chromosomal region
11p15.5 spans ~ 1 Mb and harbors two separate ICRs (Supplementary
Table 1): the telomeric one, ICR1, includes the H19/IGF2:IG-DMR,
which is methylated on the paternal allele, whereas the centromeric
one, ICR2, includes the KCNQ1OT1:TSS-DMR, which is maternally
methylated.
In the telomeric ICR1 a different chromatin architecture of the
parental alleles leads to a reciprocal expression of H19 and IGF2
(insulin-like growth factor 2). The ICR1 contains seven CTCF
(CCCTC-binding factor) target sites in the DMR, which is located
2 kb upstream of H19. The zinc-ﬁnger binding factor CTCF binds to
the maternally unmethylated ICR1 copy and thereby forms a
chromatin boundary that blocks IGF2 and promotes H19 transcription
of the maternal 11p15 genomic region. In contrast, the paternal
methylation pattern forms alternative bounds and therefore expresses
IGF2, which is involved in fetal development and growth.17 While the
contribution of IGF2 to the pathoetiology of SRS has recently been
shown,18 the function of H19 remains unknown, although it encodes
several noncoding RNAs and binds factors that are implicates in
epigenetic marks maintenance.19–21
The centromeric ICR2 in 11p15 regulates the expression of
CDKN1C, KCNQ1 (potassium channel KQT-family member 1) and
further genes and is methylated only on the maternal allele. Loss-of-
function mutations in the maternally expressed CDKN1C gene
account for 5% of sporadic and up to 50% of familial BWS cases
(Table 1) (for mutations see: http://databases.lovd.nl/shared/genes/
CDKN1C). Gain-of-function mutations are associated with growth
retardation syndromes (IMAGe syndrome, SRS). The gene encodes
a cyclin-dependent kinase inhibitor (p57KIP2) and is part of the
p21CIP2Cdk inhibitor family. Another noncoding RNA gene in
11p15, KCNQ1OT1 (also known as LIT1), starts in intron 10 of the
KCNQ1 gene. KCNQ1OT1 is expressed by the paternal allele and
probably represses the expression of the CDKN1C gene on the same
allele. Loss of methylation of the maternal ICR2 allele correlates with
an increased expression of KCNQ1OT1. In BWS, one central
physiological change caused by ICR2 (epi)mutations (hypomethyla-
tion at ICR2 as well as CDKN1C point mutations) is the reduced
expression of (functional) CDKN1C.
MOLECULAR DISTURBANCES IN SRS AND BWS
The types of mutations and epimutations in SRS and BWS affect the
same genomic regions and genes, but in an opposite manner
(Table 1). Four different types of molecular changes have been
reported: epimutations (i.e. aberrant methylation at a DMR without
a genomic alteration in the DMR itself), UPD, deletions/duplications
of the DMRs and genomic point mutations in a gene the expression of
which is regulated by the two germline DMRs. In particular, the
identiﬁcation of microduplications and microdeletions within 11p15.5
helped to deﬁne regulatory elements (i.e. DMRs, OCT4/SOX2 binding
sites, enhancer motifs) responsible for a ﬁne-tuned methylation and/or
expression of 11p15.5 factors.22,23 For molecular diagnostic testing, it
is important to keep in mind that the predominant alterations in both
disorders, the H19/IGF2:IG-DMR hypomethylation in SRS and the
upd(11)pat and 11p15 epimutations in BWS, can occur in a
mosaic state.
Silver–Russell syndrome
The majority of patients with the classical SRS phenotype7 carry
molecular changes in 11p15: hypomethylation of the H19/IGF2:IG-
DMR accounts for 40–60% of patients.7 About 1% of patients
carry duplications or deletions affecting the region 11p15.5
(Table 1): the phenotype of these carriers is inﬂuenced by the size
and gene content of the aberrations (for a review refs. 24–26). Upd
(11p)mat and point mutations in the 11p15.5-encoded genes
CDKN1C and IGF2 have only been described once each.18,27,28
Between 4 and 10% of SRS patients carry maternal UPD of
chromosome 7 (upd(7)mat) or segmental upd(7q)mat (for a review
see Eggermann et al29), in single cases chromosomal imbalances
affecting either the GRB10 gene in 7p13 or the MEST gene in 7q32
have been reported (an LOVD entry for SRS-speciﬁc structural
variations is currently in the submission process). Additionally, in a
considerable number of patients (submicroscopic) alterations of
chromosomes other than 7 and 11 may be detected.7,30,31 A number
of SRS patients exhibiting (epi)mutations in 14q32 has recently been
reported, and these molecular alterations correspond to ﬁndings in
patients with Temple syndrome (TS14, OMIM616222). TS14 is an ID
with changes affecting the IG-DMR and/orMEG3-DMR in 14q32, and
its phenotype32 overlaps with SRS (for a review see Kagami et al33). In
single cases, maternal uniparental disomy of chromosomes 16 and 20
(upd(16)mat, upd(20)mat) have been reported7,34 (for a review see
Eggermann et al35).
With the exception of patients with H19/IGF2:IG-DMR hypo-
methylation, the clinical ﬁndings in carriers of the other molecular
changes do not always ﬁt the clinical scoring suggested by different
groups (for a review see Azzi et al7). In particular, in neonates and
adults the decision on molecular testing cannot always be based on a
convincing phenotype, but testing might also be applied to patients
with less obvious growth parameters and dysmorphic signs.
Beckwith–Wiedemann syndrome
In more than 80% of BWS patients chromosome 11p15.5 epimuta-
tions or mutations can be detected affecting the ICR1 and/or ICR2
DMRs (for a review see Brioude et al10 and Mussa et al16) (Table 1).
Most BWS cases are sporadic but familial inheritance is observed in up
to 15% of all cases.11
The most frequent change is the hypomethylation of the
KCNQ1OT1:TSS-DMR, accounting for up to 60% of patients. The
second most frequent alteration in BWS is upd(11)pat, detectable in
nearly 20%. The H19/IGF2:IG-DMR is affected by hypermethylation
in 5–10% of BWS cases. For this subgroup, it has recently been shown
that OCT4/SOX2 binding site mutations or deletions encompassing
these binding sites within the ICR1 cause the aberrant methylation36
by preventing de novo methylation of the maternal allele. Deletions,
duplications and even balanced translocations in 11p15.537,38 also
contribute to the mutational spectrum, with the size and parental
origin of the affected region inﬂuencing the phenotype. CDKN1C
mutations are not only frequent in familial cases but are also of
importance in sporadic BWS with a frequency of 5%.39 In the latter
group, a signiﬁcant number of patients exhibit a cleft palate.40 Familial
cases mainly present with CDKN1C mutations (50%), chromosomal
duplications/deletions or mutations in other genes/regulative elements
(eg, OCT4/SOX2, CTCF binding sites).
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Multilocus imprinting disturbances
The association between aberrations at speciﬁc imprinted genes and
distinct congenital disorders is well known, but the number of reports
on patients with generally disturbed methylation patterns (MLID) has
increased recently (for a review see Mackay et al41). While the patients
often exhibit a speciﬁc ID phenotype, for example, BWS, molecular
testing reveals that aberrant methylation does not only affect
the disease-speciﬁc imprinted loci (eg, 11p15 in BWS) but also other
imprinted regions. In BWS, MLID is detected in ~ 25% of patients
with hypomethylation of the KCNQ1OT1:TSS-DMRs, and in SRS in
7–10% of H19/IGF2:IG-DMR patients (Table 1). A common cause of
MLID has not yet been reported, but mutations in trans-acting genes/
factors have been identiﬁed in some cases.42–44 Thus, whole-exome/
genome sequencing strategies or candidate gene analyses might be
considered in these patients on a research basis and in cooperation
with reference centers. Assisted reproductive technologies have also
been associated with an increased risk of MLID.45
MOLECULAR GENETIC TESTING STRATEGIES
Several diagnostic assays for the molecular diagnosis of SRS and BWS
have been developed (Table 2), but the decision on the tests to be
applied in a laboratory depends on many factors, including the
equipment of the laboratory, the methodological experience, the
pattern of referral, the in-house guidelines for diagnostic workup
and the national strategy of diagnostic workup.
In any case, the laboratory has to be aware of the advantages and
limitations of a test, and the diagnostic workup should follow the
diagnostic algorithms shown in Figure 2. This diagnostic algorithm
refers to samples received to conﬁrm the clinical diagnosis of SRS or
BWS. It does not account for cases referred for UPD analyses based on
chromosomal ﬁndings or a precedent (family) history with an already
known molecular disturbance.
First step: Methylation test for the 11p15.5 DMRs in SRS and BWS
and for chromosome 7 in SRS
In both SRS and BWS, a methylation-sensitive (methylation-speciﬁc
(MS)) approach targeting the two DMRs in 11p15.5 is recommended
(Figure 2). In case of SRS, ﬁrst-step analysis also has to include
chromosome 7 methylation testing. Indeed, the majority of patients
with chromosome 7 alterations carry an UPD of the whole chromo-
some, but there is a growing number on reports of patients with a
segmental UPD for 7q (upd(7q)mat) including MEST.29 Furthermore,
several patients with copy number variations affecting either the
GRB10 locus in 7p13 or the MEST imprinted region in 7q32 have
been reported, thus both imprinted regions have to be analyzed.
Further procedure for SRS and BWS after a positive testing result
With a positive result of methylation testing for 11p15.5 (or chromo-
some 7), the clinical diagnosis is conﬁrmed. However, the discrimina-
tion between the different molecular subtypes is required
(epimutations, UPDs, copy number variations (CNVs), translocations)
as the basis for a personalized clinical management in BWS, and a
directed genetic counseling in both disorders.16 Depending on the
applied method, this discrimination may be possible in a single
analysis or multiple tests have to be carried out (Figure 2). It depends
on the diagnostic repertoire of the lab whether it offers this workup or
whether it forwards the samples to reference centers. In case only the
ﬁrst step of diagnosis is performed, the required subsequent diagnostic
steps and putative molecular results must be included in the report,
including the associated recurrence risks (Figure 2 and Table 1).
Further procedure for SRS after a negative testing result
In case of a negative 11p15.5 and chromosome 7 testing result, testing
for TS14-associated alterations and molecular karyotyping can be
considered (Figure 2).
In contrast, mutations in CDKN1C and IGF2 have only been
described in a single family each,18,27 and screening studies in larger
cohorts of sporadic SRS patients have so far been negative,
and therefore these genes should only be analyzed after a careful
re-evaluation of clinical ﬁndings and family history. The sequencing
should not be included in routine diagnostic analysis for SRS.
Additionally, differential diagnoses have to be considered (for a review
see Saal1).
Indeed, further molecular changes have been identiﬁed in single
cases (eg, upd(16)mat, upd(20)mat); thus, if warranted by the clinical
features and/or family history of the patient, testing for these very rare
(epi)mutations may be considered.
Figure 1 The imprinted gene cluster in 11p15.5. It is divided in two functional domains whose imprinting is dependent on distinct ICRs (H19/IGF2:IG-DMR,
KCNQ1OT1:TSS-DMR). (Filled boxes, protein coding genes; empty boxes, noncoding genes; Ω miRNAs; ﬁlled lollipops, methylated regions; empty lollipops,
unmethylated regions; red, genes expressed from the maternal (mat) chromosome; blue, genes expressed from the paternal (pat) chromosome. Arrows above
the genes, transcription direction of sense genes; arrows below the genes, transcription direction of anti-sense genes)
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The complex molecular workup in SRS, including differential
diagnosis (see below) can, in part, be circumvented by replacing
single-step analyses for each imprinted locus by tests targeting different
DMRs simultaneously in the same run ('multilocus testing'), thereby
allowing the one-step identiﬁcation of aberrant methylation patterns at
different DMRs caused by other imprinting defects (eg, TS14, MLID)
or uniparental diploidy.
Further procedure for BWS after a negative testing result
In case of a negative result of the methylation test for the 11p15.5
DMRs in a BWS patient, sequencing of the coding exons and the
exon–intron boundaries of the CDKN1C gene should be considered in
case of a positive family history, cleft palate and abdominal wall defect
(umbilical hernia or exomphalos).
Nevertheless, nearly 30% of patients with a characteristic BWS
phenotype still remain without a molecular diagnosis, and differential
diagnoses should also be discussed after clinical re-evaluation
(for a review see Shuman et al11).
Mosaicism in SRS and BWS
Mosaicism affects the majority of molecular disturbances in SRS and
BWS,7,41 that is, in a given sample the (epi)genetic defect is present
only in a fraction of the total number of cells. Low-level mosaicism
within a tissue may not be detected because of the detection limit of
the methods used, leading to false-negative results. The fraction
of aberrant cells may vary among different tissues. After clinical
re-evaluation testing other tissues might be considered to exclude
tissue-speciﬁc mosaicism.
MOLECULAR GENETIC TESTING METHODS
Several techniques have been implemented in the molecular
diagnostic testing algorithm of both SRS and BWS, and as
the ﬁrst EMQN pilot schemes for SRS and BWS in 2014
showed (http://www.imprinting-disorders.eu/wp-content/uploads/
2015/07/EMQN-SRS-Summary-Report.pdf; http://www.imprinting-
disorders.eu/wp-content/uploads/2015/07/EMQN-BWS-Summary-
Report.pdf), different methods (Table 2) are suitable for diagnostic
analysis. However, the choice of a technique to identify 11p15.5
and chromosome 7 disturbances should consider the loci to be
analyzed and their precise genomic localization, the investigated
tissue and the spectrum of occurring mutations and epimutations.
Furthermore, none of these tests are certiﬁed for diagnostic use.
Therefore, they have to be fully validated in the laboratory, and the
normal reference ranges may be challenged by the possible
occurrence of mosaicism. Furthermore, MS-speciﬁc tests should
contain controls for complete digestion or bisulﬁte treatment.
Several methods do not allow the discrimination between the
different types of molecular changes (upd, CNVs, epimutations)
(Table 2), in this situation a combination of techniques has to be
applied.
MS-speciﬁc techniques
Assays targeting altered methylation patterns can be roughly sub-
divided into two groups, those based on bisulﬁte-converted DNA and
those using methylation-sensitive restriction enzymes (Table 2). With
the exception of Southern blotting, all MS assays are based on the
hybridization of short probes or primers; therefore, these tests are
prone to be affected by single-nucleotide polymorphisms (SNPs)
inﬂuencing the hybridization efﬁcacy of complementary probe–primer
sequences. Thus, false-positive results might occur, and positive results
Figure 2 Diagnostic algorithm for SRS (a) and BWS (b). For both disorders, methylation-speciﬁc tests for both imprinted regions in 11p15.5, and in case of
SRS for the DMRs on chromosome 7 are recommended. The lab has to be aware of the possible outcomes and their interpretation. In case of a positive
testing result, the subsequent discrimination is mandatory and has at least to be suggested in the report. Ditto, the further proceeding after a negative result
has to be advised by the reporting geneticists.
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should therefore be conﬁrmed – if available – by a second technique
or other probes–primers, or at least by a second independent run.
The EMQN pilot scheme revealed that MS-speciﬁc multiplex
ligation probe-dependent ampliﬁcation (MLPA) is by far the most
widely used test (480%) in routine diagnostics for SRS and BWS and
will be described below in more detail; for the other tests see Table 2.
MS-MLPA (Supplementary Figure 1) as an adaption to normal
MLPA provides a tool to simultaneously detect changes of copy
numbers and methylation. DNA is digested with a methylation-
sensitive restriction enzyme after hybridization of the MLPA probes.
Comparison of peak heights of undigested and digested DNA indicates
the methylation level of a particular probe. Monitoring complete
digestion is an essential quality control of the experiment. MS-MLPA
just requires general laboratory equipment (thermocycler, capillary
electrophoresis platform), and the bioinformatics analysis can be
performed by freely available or commercially available software
packages (eg, Coffalyser.Net (JSI, Freiburg, Germany); GeneMarker
software (SoftGenetics, State College, PA, USA)). For data normal-
ization, the parallel analysis of samples with normal genotype/
epigenotype is recommended by the manufacturer. Quality and purity
of DNA is an essential prerequisite for deﬁnitive MLPA data
interpretation, and the labs should therefore be aware of it.
In principle, DNA samples isolated with different methods and from
different tissues might be used in parallel in the same experiment, but
the methylation pattern in the tissues tested must be known and
identical to the tissue tested. According to general good practice
laboratory guidelines, a non-template control and at least one positive
control should be run in parallel. Several MS-MLPA Kits are
commercially available from MRC Holland (Amsterdam, Netherlands;
http://www.mrc-holland.com).
Chromosome 11p15.5 testing (ME030 BWS/RSS Kit, MRC Holland).
The assay includes more than 20 probes speciﬁc for the region
11p15.5. Two probes serve as a control of the HhaI digestion in the
methylation run. As controls for copy number quantiﬁcation, probes
outside 11p15.5 are included. Ten of the 11p15.5-speciﬁc probes are
methylation-speciﬁc and target the germline H19/IGF2:IG-DMR (four
probes) and KCNQ1OT1:TSS-DMR (four probes), additionally one
probe each for the somatic DMRs of IGF2 and CDKN1C is included.
The analysis of the same germline DMR by several probes reduces the
risk of false-positive or false-negative results due to SNPs. Further-
more, if one probe fails and artiﬁcial hypomethylation of single probes
occurs (eg, due to DNA extraction method or cell culture), there are
three remaining probes to assess the methylation status.
The dosage analysis of the kit allows the identiﬁcation of duplica-
tions and deletions in 11p15.5. In cases of a large duplication affecting
the whole 11p15.5 region all probes are affected. Additionally, it also
detects smaller CNVs restricted to parts of the region. However,
the precise size and content of 11p15.5 CNVs should be determined
by further suitable methods (eg, molecular karyotyping, qPCR).
Owing to the opposite imprinting patterns of the two 11p15.5
DMRs (H19/IGF2:IG-DMR is paternally methylated and KCNQ1OT1:
TSS-DMR is maternally methylated), the methylation analysis of the
ME030 assay allows both the identiﬁcation and discrimination
between the epimutations, and, in combination with the dosage
analysis, between epimutations, UPDs and CNVs affecting both
DMRs. Indeed, segmental UPDs of only one of the DMRs might be
indistinguishable from isolated epimutations, but these have not
yet been reported. In these situations, microsatellite typing might be
applied.
Chromosome 7 testing (ME032 UPD7-UPD14 Kit, MRC Holland).
With this assay, upd(7)mat can be identiﬁed (Supplementary
Figure 1). Similar considerations as for the interpretation of the
ME030 Kit should be made, but in contrast to the 11p15.5 assay, and
because of the methylation status of the targeted DMRs, a
Figure 2 Continued.
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differentiation between UPD and epimutations is not possible and
requires additional workup. However, with the exception of isolated
hypermethylation of the GRB10 DMR,46 epimutations have not yet
been reported. The advantage of this assay is the inclusion of
imprinted loci on chromosomes 14 and 6, and thus molecular changes
associated with TS14 as well as some MLID patterns can be detected in
parallel.
Non-MS assays
Depending on the design and informativity of the initially applied MS
test, an identiﬁcation, conﬁrmation and further characterization of
genomic alterations (CNVs, SNPs, UPD) might be required. For these
purposes, the following assays have been implemented with different
advantages and limitations (Table 2):
Microsatellite typing (short tandem repeat typing, STR) is frequently
applied for detection of UPDs, in particular in prenatal testing.
In addition to the patient’s DNA sample, a sample from at least one
parent is required to delineate the parental origin of the two STR
alleles. For whole arm UPD detection STRs are an efﬁcient and
inexpensive tool, but it has to be considered that a discrimination
between (mosaic)UPD and deletions or duplications are not possible
in every case (Supplementary ﬁgure 2). Furthermore, segmental UPDs
of small fragments might escape detection. In case UPD has been
determined solely by STR typing, the lab should be aware of
the scenario of non-paternity. Microsatellite markers suitable for
UPD analysis in context with SRS and BWS should be selected on
the basis of their informativity (PIC40.7) and their genomic
localization (markers used in diagnostic testing are listed in
Supplementary table 2).
Molecular karyotyping (Chromosomal Microarray) is a suitable
method to determine the size and gene content of CNVs, but it has
to be considered that the probe content of arrays is not standardized,
and different assays have different coverages of the regions of interest.
Therefore, very small imbalances might remain undetected and might
rather be analyzed by qPCR. By SNP array analysis, uniparental
isodisomic segments can in principal be detected and are therefore
applicable in BWS testing,47 but small isodisomic segments cannot be
discriminated from small homozygous stretches, and heterodisomy
can only be identiﬁed by parallel analysis of parental samples and
the use of additional bioinformatic tools. aCGH is not suitable for
UPD detection.
Identiﬁcation of single-nucleotide variants/point mutations should
be performed by genomic sequencing, analyzing the genomic sequences
deﬁned as reference sequences (Supplementary Table 2). In case of
sequencing genes (eg, CDKN1C), the appropriate guidelines (eg, of the
American College of Medical Genetics and Genomics and the
Association for Molecular Pathology (2015)48 or the Association for
Clinical Genetic Sciences49 (http://www.acgs.uk.com/media/774853/
evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-
_ﬁnalpdf.pdf) should be followed. It must be noted that sequencing
analysis of CDKN1C is complex as the gene is GC-rich and contains
several non-pathogenic in-frame deletion variants.
Future methodological developments
Owing to the heterogeneous molecular ﬁndings in SRS and BWS, and
the limitations of several of the currently applied tests, the diagnostic
workup including discrimination of the molecular subtypes might
become time-consuming and expensive. Therefore, the development
of multilocus tests is in progress, either on the basis of conventional
MS-MLPA by combining probes from different imprinted loci or by
next-generation sequencing approaches. The latter harbors the
potential to be more sensitive, as massive parallel sequencing might
allow the detection of low-level mosaicism, and comprehensive
inclusion of possible genomic and epigenetic changes.
INTERPRETATION OF DIAGNOSTIC TESTING RESULTS
The precise identiﬁcation and discrimination of the mutations
or epimutations in patients referred with SRS or BWS features is the
prerequisite for clinical management in BWS and a well-directed
genetic counseling.
LOM at one of the 11p15.5 DMRs in SRS and BWS/MLID
LOM (Hypomethylation) at one of the two DMRs in 11p15.5
represents the most frequent diagnostic ﬁnding in the two 11p15.5-
associated IDs (Table 1) and their identiﬁcation conﬁrms the clinical
diagnosis of SRS and BWS, respectively. In general, the recurrence risk
is low in these molecular subgroups,
However, there are reports on families with two BWS sibs,43,50 with
one sib showing a KCNQ1OT1:TSS-DMR hypomethylation and the
second one showing the same epimutation but as part of an MLID.
Although this situation seems to be rare, it illustrates that MLID
also has to be considered in BWS testing. In general, MLID accounts
for 7–10% of SRS with H19/IGF2:IG-DMR hypomethylation, and for
25% of patients with KCNQ1OT1:TSS-DMR hypomethylation in
BWS. Assuming a general frequency for this molecular subtype of
50% in BWS cohorts, MLID is detectable in 12.5% of BWS patients.
In case of MLID the recurrence risk is difﬁcult to estimate because
mutations in genes associated with a generally disturbed methylation
have only been recently reported. The disease-causing variants may
either have an autosomal recessive effect (eg, ZFP57 in transient
neonatal diabetes mellitus42) or represent the recently deﬁned
maternal effect mutations, that is, the maternal genotype is responsible
for the aberrant methylation in her offspring.43,44
GOM at one of the DMRs in 11p15.5
Up to now, isolated GOM (hypermethylation) in 11p15.5 has been
reported for BWS: hypermethylation of the H19/IGF2:IG-DMR might
be difﬁcult to detect in case of a low-level mosaicism. Although GOM
mainly occurs sporadically, up to 20% of GOM patients carry genomic
disease-causing variants within the OCT4/SOX2 binding site (BS)
5′ to the DMR36 and referral to specialist research centers can be
considered. In case of detection of an OCT4/SOX2 BS pathogenic
variants, it has to be evaluated individually. Another group of genomic
variants affecting the H19/IGF2:IG-DMR are microdeletions that
reduce the number of CTCF target sites and might be associated with
the inactivation of the DMR: their size and spacing inﬂuence the
degree of DNA methylation and the clinical phenotype.22 Careful
characterization of these microdeletions is therefore needed to predict
recurrence risks and phenotypical outcomes. In these cases, analysis
of parental DNA should be considered to determine the mode of
transmission, and the recurrence risk is 50% in the event of a
maternally inherited disease-causing variant.
In SRS, GOM of the KCNQ1OT1:TSS-DMR is extremely rare and
can be due to a small duplication of the maternal allele, thus requiring
a careful workup by a specialized lab.
Detection of both LOM/GOM at the two 11p15.5 DMRs
Parallel occurrence of both LOM and GOM at the two 11p15.5 DMRs
in the same patient either indicates UPD or CNVs. To discriminate
these two alterations copy number analysis is required.
In BWS upd(11)pat contributes to up to 20% of cases, and it is
mainly segmental (ie, restricted to the 11p15.5 region or the short arm
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of chromosome 11, and isodisomic),47 but some cases with upd(11)
pat affecting the whole chromosome have been reported. STR
determination of uniparental isodisomy can be hampered by the
mosaic presence of the disturbance. Therefore, it might not only
become a qualitative analysis but also a quantitative one. For upd(11)
pat a postzygotic origin has been delineated and the recurrence risk is
therefore not increased. Particular attention should be directed to
(mosaic) uniparental diploidy (for a review see Kalish et al51). This
genetic constitution is associated with further features additional to
those of BWS, in particular with a severely increased risk for a broad-
spectrum of (embryonal) tumors, and clinical surveillance and
management is not covered by the conventional BWS tumor
programs. A further problem in upd(11)pat is the variable degree of
mosaicism, making the identiﬁcation difﬁcult or leading to a false
interpretation: the increase of hybridization of the H19/IGF2:IG-DMR
probes might be weaker than the decrease of the KCNQ1OT1:TSS-
DMR probes, and might escape the detection.47 The application of a
second method might be helpful to conﬁrm the molecular suspicion of
UPD, even in case the H19/IGF2:IG-DMR is in the upper control range.
Upd(11)mat is extremely rare in SRS,28 and only one case with
mosaic maternal uniparental diploidy has been reported.
(Submicroscopic) chromosomal imbalances in 11p15.5 (CNV), that
is, duplications, conﬁrm the clinical diagnosis of SRS or BWS. After
identiﬁcation of a CNV in an SRS or a BWS patient, molecular
karyotyping is indicated to conﬁrm the abnormality and to determine
its size as the content of genes and regulative elements of the
aberration might explain additional clinical features of the patient,
which might not belong to the SRS/BWS spectrum (an LOVD entry
for SRS-speciﬁc CNVs is currently in the submission process).
A cytogenetic/molecular-cytogenetic analysis of the patients and their
parents might help to determine the nature of the imbalance and to
estimate the recurrence risk in case of a familial rearrangement.
In case of a familial rearrangement, an autosomal-dominant
inheritance with phenotypic expression depending on the sex of the
contributing parent can be expected: in case the duplication affects
the whole 11p15.5 region of the paternal allele, a BWS phenotype is
probable, whereas an SRS-like clinical picture will occur in case the
maternal chromosome carries the duplication. Thus, both phenotypes
may occur in the same family.26
Smaller CNVs affecting only one of the 11p15.5 DMRs
Smaller duplications or deletions affecting only parts of the two
11p15.5 imprinting regions, may cause BWS, SRS or a normal
phenotype, depending on the regulative and coding DNA sequences
involved in the rearrangement and the sex of the contributing parent
(for a review see Begemann et al25). Thus, a careful workup has to be
applied in case of duplications or deletions of the imprinted regions in
11p15.5, and the geneticist has to estimate recurrence risks on the
basis of the up-to-date literature.
Upd(7)mat in SRS patients
As the vast majority of upd(7)mat are products of a trisomy rescue,
the recurrence risk is generally low and the only predisposing factor is
advanced maternal age. However, two cases have been reported in
which the upd(7)mat was the result of a familial chromosomal
translocation, in this situation the recurrence risk is increased.52,53
Thus, cytogenetic/molecular-cytogenetic analysis should be considered
whenever there is a chance for a chromosomal aberration (eg, if a
translocation or aberration in the family involving chromosome 7 or
11 is known), but need not be generally offered to UPD cases.
Pathogenic variants (in CDKN1C and IGF2)
In BWS, CDKN1C mutation analysis has to be considered owing to its
frequency of up to 50% in familial cases. Indeed, in some labs it
is performed as the ﬁrst diagnostic step in families with BWS and in
BWS patients with cleft palate. If a pathogenic variant in one of the
genes is identiﬁed, genetic counseling should be offered and a
segregation analysis in the families can be discussed. Comparable to
chromosomal rearrangements, the recurrence risk is 50% for
CDKN1C and IGF2 mutations, but it depends on the sex of the
transmitting parent. A BWS phenotype will occur if a CDKN1C
disease-causing variant is inherited from the mother, or if a de novo
mutation affects the maternal allele, whereas there is no (or minimal)
phenotypic effect in case the paternal gene copy carries the pathogenic
variant. For SRS, maternal inheritance of a missense mutation located
in the PCNA-binding domain of CDKN1C may lead to an SRS or
IMAGe phenotype, whereas paternal inheritance of an IGF2 mutation
results in SRS.
Normal chromosomes 11p15.5 and 7 methylation results in SRS
Normal chromosomes 11p15.5 and 7 methylation patterns do not rule
out the clinical diagnosis of SRS, currently 30–40% of patients remain
without a molecular conﬁrmation of the clinical diagnosis.7 In routine
screening without strict diagnostic inclusion criteria the detection rate
is even lower.8 As mentioned before, molecular changes in the
imprinted 14q32 region signiﬁcantly contribute to the mutation
spectrum7,8,33 and therefore overlap with TS14. TS14 testing is thus
suggested as a further diagnostic step for patients with strong clinical
suspicion of SRS, and it is already included in a commercially available
MS-MLPA assay. Similar to that for SRS and BWS, TS14 testing
should consist of appropriate assays to discriminate between the
different molecular subgroups.
Furthermore, molecular karyotyping is indicated as a further
molecular diagnostic step in patients with clear phenotypic features,
and signiﬁcantly contributes to the clariﬁcation of the cause of
the phenotype and recurrence risks.
Owing to the mosaic tissue distribution of 11p15.5 epimutations,2
testing of other tissues (eg, ﬁbroblasts) might also be considered after a
careful clinical re-evaluation.
Normal 11p15.5 methylation result in BWS
The aforementioned (epi)mutations in the two germline DMRs in
11p15.5 account for 70–80% of patients with BWS, thus a negative
result does not rule out BWS (Table 1). However, epimutations and
upd(11)pat might escape detection owing to uneven mosaic
distribution.54 Thus, the analysis of another tissue for epimutation
might be considered if the routine 11p15.5 testing is negative.
For BWS no major further molecular subgroups have been
identiﬁed, but differential diagnosis should also be considered.
REPORTING
For different reasons it is not recommended to use the same templates
for sample referral, reporting and interpretation of ﬁndings for BWS
and SRS.
In general, the format of the reports has to correspond to general
guidelines of reporting molecular genetic results according to Inter-
national and the National Regulators (eg, from the Association for
Clinical Genetic Science (Part of the British Society for Genetic
Medicine; http://www.acgs.uk.com/media/949852/acgs_general_genetic_
laboratory_reporting_recommendations_2015.pdf). Laboratories reporting
(BWS/SRS) testing results should participate annually at least in
external quality assessment. It is recommended that testing laboratories
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are accredited to international standards, for example, ISO 15189 or
equivalent. In particular, it is essential that the report contains the
following items:
 unequivocal patient identiﬁers, numbering of pages,
 the reason for referral,
 source of DNA sample (eg, blood, buccal smear, amniocytes),
 a consistent naming of the analyzed DMRs should be used in the
same report, and recently a common nomenclature has been
suggested the European Network of Congenital Imprinting Dis-
orders EUCID.net (www.imprinting-disorders.eu)(Supplementary
Table 1). The nomenclature of genomic mutations has to be in
accordance with the suggestions of the HGVS (http://www.hgvs.org/
mutnomen/),
 applied methods and statement on the limitations and sensitivities
including detection of mosaicism. Appropriate references should be
given, if commercial kits are used, the kit version has to be
mentioned (eg, ME030-C3; http://www.mrc-holland.com),
 the precise result description,
 interpretation of diagnostic testing results (see above),
 statement whether the clinical diagnosis is conﬁrmed or not,
 statement on the signiﬁcance of the molecular results for the clinical
management: for SRS, the certainty of the molecular genetic
diagnosis aids medical management and precludes further investiga-
tions for short stature. However, therapeutic measures such as
growth hormone treatment, physiotherapy or managing of hypo-
glycemic are based on clinical symptoms rather than on the genetic
diagnosis, and should therefore not be suggested in the report. In
case of BWS, tumor surveillance should be advised in the report
according to the national guidelines and as suggested by the Clinical
Utility Gene card for BWS.9
 in case the results of only single steps of the diagnostic algorithm
(Figure 2) are reported, the consecutive steps must be suggested,
 genetic counseling has to be recommended, and recurrence risk has
to be mentioned.
PRENATAL TESTING
The growing knowledge on the molecular basis of SRS and BWS and
the increasing number of positively tested patients results in an
increasing demand for prenatal testing for these diseases. Owing to
the complexity of molecular testing and the numerous questions that
raised the context of prenatal testing, and ranging from methodolo-
gical questions to ethical topics, the authors have addressed this topic
separately.55,56 In principal, prenatal testing might be offered in
speciﬁc situations, but the decision on prenatal testing for SRS or
BWS requires careful and comprehensive discussions (including the
limitations of methods and information value, ethical issues) between
the families, the genetic counselors, the obstetrics and laboratories.
DIFFERENTIAL DIAGNOSIS
In both 11p15.5-associated IDs, the clinical diagnosis is often difﬁcult
because of its variable presentation during childhood and adolescence
(eg, with age the facial characteristics tend to become attenuated in
SRS, and normalized in BWS); furthermore, the molecular and
phenotypic ﬁndings overlap with other IDs and syndromes. Thus,
after exclusion of the major molecular changes detectable in SRS or
BWS (Figure 2), a clinical re-evaluation should be performed and
differential clinical diagnoses should be considered (eg, IMAGe
syndrome, 3M syndrome for SRS; Sotos, Weaver, Perlman, Simp-
son–Golabi–Behmel syndrome for BWS).1,11 Recent reports indicate
the contribution of new, so far neglected loci and chromosomes to
SRS: patients with upd(16)mat or upd(20)mat show symptoms
overlapping with SRS.7,34 However, it is still too early to include
them in routine diagnostic workups, and they should rather be
included in research strategies.
CONCLUDING REMARKS
These guidelines are based on the knowledge acquired from peer-
reviewed and published data, as well as observations of the authors
in their practice. Current practice of molecular testing and
reporting of SRS and BWS was assessed by a ﬁrst external pilot
quality assessment scheme organized by the EMQN in 2014. In the
two-pilot schemes for SRS and BWS, a total of 42 laboratories
from 19 European and non-European countries for BWS and 31
diagnostic centers from 14 countries for SRS participated. Based on
the results from these schemes and in context with activities of the
European Network of Imprinting Disorders (EUCID.net) towards
a consensus in diagnostics and management of SRS and BWS, best
practice guidelines have been developed. Members of institutions
working in the ﬁeld of SRS and BWS diagnostics were invited to
comment, and in the light of feedback amendments were made.
The ﬁnal document was ratiﬁed in the course of an EMQN best
practice guideline meeting for 11p15.5 IDs on 3 October 2015 and
in accordance with the general SRS and BWS consensus guidelines,
which are in preparation.
These guidelines can only provide a snapshot of current knowledge
at the time of manuscript submission. Readers are advised to keep up
with the literature.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
The authors KE, JB, FB, KB, SR, ZT, DM, GM, IN, PL, LS, MB, DP, ERM,
MM, AR, PL, KG, DJM and TE are members of the European Network of
Congenital Imprinting Disorders (EUCID.net), supported by COST (BM1208).
TE, KB and DP are supported by the BMBF (grant number 01GM115A/B).
1 Saal HM: Russell-Silver Syndrome; in Pagon RA, Adam MP, Ardinger HH et al: (eds):
GeneReviews(R). Seattle, WA, USA: University of Washington, 1993.
2 Azzi S, Blaise A, Steunou V et al: Complex tissue-speciﬁc epigenotypes in Russell–
Silver syndrome associated with 11p15 ICR1 hypomethylation. Hum Mutat 2014; 35:
1211–1220.
3 Wakeling EL, Amero SA, Alders M et al: Epigenotype–phenotype correlations in
Silver–Russell syndrome. J Med Genet 2010; 47: 760–768.
4 Binder G, Liebl M, Woelﬂe J, Eggermann T, Blumenstock G, Schweizer R: Adult height
and epigenotype in children with Silver–Russell syndrome treated with GH. Horm Res
Paediatr 2013; 80: 193–200.
5 Takenouchi T, Awazu M, Eggermann T, Kosaki K: Adult phenotype of Russell–Silver
syndrome: a molecular support for Barker–Brenner's Theory. Congenit Anom (Kyoto)
2015; 55: 167–169.
6 Bliek J, Terhal P, van den Bogaard MJ et al: Hypomethylation of the H19 gene causes
not only Silver–Russell syndrome (SRS) but also isolated asymmetry or an SRS-like
phenotype. Am J Hum Genet 2006; 78: 604–614.
7 Azzi S, Salem J, Thibaud N et al: A prospective study validating a clinical scoring
system and demonstrating phenotypical-genotypical correlations in Silver–Russell
syndrome. J Med Genet 2015; 52: 446–453.
8 Eggermann T, Heilsberg AK, Bens S et al: Additional molecular ﬁndings in
11p15-associated imprinting disorders: an urgent need for multi-locus testing.
J Mol Med (Berl) 2014; 92: 769–777.
9 Eggermann T, Algar E, Lapunzina P et al: Clinical utility gene card for:
Beckwith–Wiedemann syndrome. Eur J Hum Genet 2014; e-pub ahead of print 3 July
2013; doi:10.1038/ejhg.2013.132.
10 Brioude F, Lacoste A, Netchine I et al: Beckwith–Wiedemann syndrome: growth pattern
and tumor risk according to molecular mechanism, and guidelines for tumor
surveillance. Horm Res Paediatr 2013; 80: 457–465.
Molecular genetic testing for 11p15 imprinting disorders
K Eggermann et al
1386
European Journal of Human Genetics
11 Shuman C, Beckwith JB, Smith AC, Weksberg R: Beckwith–Wiedemann syndrome; in
Pagon RA, Adam MP, Ardinger HH et al: (eds): GeneReviews (R). Seattle, WA, USA:
University of Washington, 1993.
12 Elliott M, Bayly R, Cole T, Temple IK, Maher ER: Clinical features and natural history of
Beckwith–Wiedemann syndrome: presentation of 74 new cases. Clin Genet 1994; 46:
168–174.
13 DeBaun MR, Tucker MA: Risk of cancer during the ﬁrst four years of life in children
from the Beckwith–Wiedemann Syndrome Registry. J Pediatr 1998; 132: 398–400.
14 Ibrahim A, Kirby G, Hardy C et al: Methylation analysis and diagnostics of
Beckwith–Wiedemann syndrome in 1,000 subjects. Clin Epigenet 2014; 6: 11.
15 Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A: Microdeletions in
the human H19 DMR result in loss of IGF2 imprinting and Beckwith–Wiedemann
syndrome. Nat Genet 2004; 36: 958–960.
16 Mussa A, Russo S, De Crescenzo A et al: (Epi)genotype–phenotype correlations in
Beckwith–Wiedemann syndrome. Eur J Hum Genet 2016; 24: 183–190.
17 Constancia M, Hemberger M, Hughes J et al: Placental-speciﬁc IGF-II is a major
modulator of placental and fetal growth. Nature 2002; 417: 945–948.
18 Begemann M, Zirn B, Santen G et al: Paternally inherited IGF2 mutation and growth
restriction. N Engl J Med 2015; 373: 349–356.
19 Cai X, Cullen BR: The imprinted H19 noncoding RNA is a primary microRNA precursor.
Rna 2007; 13: 313–316.
20 Monnier P, Martinet C, Pontis J, Stancheva I, Ait-Si-Ali S, Dandolo L: H19 lncRNA
controls gene expression of the Imprinted Gene Network by recruiting MBD1. Proc Natl
Acad Sci USA 2013; 110: 20693–20698.
21 Schoenfelder S, Smits G, Fraser P, Reik W, Paro R: Non-coding transcripts in the H19
imprinting control region mediate gene silencing in transgenic Drosophila. EMBO Rep
2007; 8: 1068–1073.
22 Beygo J, Citro V, Sparago A et al: The molecular function and clinical phenotype of
partial deletions of the IGF2/H19 imprinting control region depends on the spatial
arrangement of the remaining CTCF-binding sites. Hum Mol Genet 2013; 22:
544–557.
23 De Crescenzo A, Sparago A, Cerrato F et al: Paternal deletion of the 11p15.5
centromeric-imprinting control region is associated with alteration of imprinted gene
expression and recurrent severe intrauterine growth restriction. J Med Genet 2013; 50:
99–103.
24 Prawitt D, Enklaar T, Gartner-Rupprecht B et al: Microdeletion and IGF2 loss of
imprinting in a cascade causing Beckwith–Wiedemann syndrome with Wilms' tumor.
Nat Genet 2005; 37: 785–786, 786–787.
25 Begemann M, Spengler S, Gogiel M et al: Clinical signiﬁcance of copy number
variations in the 11p15.5 imprinting control regions: new cases and review of the
literature. J Med Genet 2012; 49: 547–553.
26 Cardarelli L, Sparago A, De Crescenzo A et al: Silver–Russell syndrome and Beckwith–
Wiedemann syndrome phenotypes associated with 11p duplication in a single family.
Pediatr Dev Pathol 2010; 13: 326–330.
27 Brioude F, Oliver-Petit I, Blaise A et al: CDKN1C mutation affecting the PCNA-binding
domain as a cause of familial Russell–Silver syndrome. J Med Genet 2013; 50:
823–830.
28 Bullman H, Lever M, Robinson DO, Mackay DJ, Holder SE, Wakeling EL: Mosaic
maternal uniparental disomy of chromosome 11 in a patient with Silver–Russell
syndrome. J Med Genet 2008; 45: 396–399.
29 Eggermann T, Schonherr N, Jager S et al: Segmental maternal UPD(7q) in Silver–
Russell syndrome. Clin Genet 2008; 74: 486–489.
30 Bruce S, Hannula-Jouppi K, Puoskari M et al: Submicroscopic genomic alterations in
Silver–Russell syndrome and Silver–Russell-like patients. J Med Genet 2010; 47:
816–822.
31 Spengler S, Begemann M, Ortiz Bruchle N et al: Molecular karyotyping as a relevant
diagnostic tool in children with growth retardation with Silver–Russell features.
J Pediatr 2012; 161: 933–942.
32 Ioannides Y, Lokulo-Sodipe K, Mackay DJ, Davies JH, Temple IK: Temple syndrome:
improving the recognition of an underdiagnosed chromosome 14 imprinting disorder:
an analysis of 51 published cases. J Med Genet 2014; 51: 495–501.
33 Kagami M, Mizuno S, Matsubara K et al: Epimutations of the IG-DMR and the MEG3-
DMR at the 14q32.2 imprinted region in two patients with Silver–Russell syndrome-
compatible phenotype. Eur J Hum Genet 2015; 23: 1062–1067.
34 Mulchandani S, Bhoj EJ, Luo M et al: Maternal uniparental disomy of chromosome 20:
a novel imprinting disorder of growth failure. Genet Med 2015; 18: 309–315.
35 Eggermann T, Perez de Nanclares G, Maher ER et al: Imprinting disorders: a group of
congenital disorders with overlapping patterns of molecular changes affecting
imprinted loci. Clin Epigenet 2015; 7: 123.
36 Abi Habib W, Azzi S, Brioude F et al: Extensive investigation of the IGF2/H19
imprinting control region reveals novel OCT4/SOX2 binding site defects associated with
speciﬁc methylation patterns in Beckwith–Wiedemann syndrome. Hum Mol Genet
2014; 23: 5763–5773.
37 Smith AC, Suzuki M, Thompson R et al: Maternal gametic transmission of transloca-
tions or inversions of human chromosome 11p15.5 results in regional DNA hyper-
methylation and downregulation of CDKN1C expression. Genomics 2012; 99: 25–35.
38 Kaltenbach S, Capri Y, Rossignol S et al: Beckwith–Wiedemann syndrome and long QT
syndrome due to familial-balanced translocation t(11;17)(p15.5;q21.3) involving the
KCNQ1 gene. Clin Genet 2013; 84: 78–81.
39 Lam WW, Hatada I, Ohishi S et al: Analysis of germline CDKN1C (p57KIP2) mutations
in familial and sporadic Beckwith–Wiedemann syndrome (BWS) provides a novel
genotype-phenotype correlation. J Med Genet 1999; 36: 518–523.
40 Brioude F, Netchine I, Praz F et al: Mutations of the imprinted CDKN1C gene as a
cause of the overgrowth Beckwith–Wiedemann syndrome: clinical spectrum and
functional characterization. Hum Mutat 2015; 36: 894–902.
41 Mackay DJ, Eggermann T, Buiting K et al: Multilocus methylation defects in imprinting
disorders. Biomol Concepts 2015; 6: 47–57.
42 Mackay DJ, Callaway JL, Marks SM et al: Hypomethylation of multiple imprinted loci in
individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat
Genet 2008; 40: 949–951.
43 Meyer E, Lim D, Pasha S et al: Germline mutation in NLRP2 (NALP2) in a familial
imprinting disorder (Beckwith–Wiedemann Syndrome). PLoS Genet 2009; 5:
e1000423–e1000423.
44 Docherty LE, Rezwan FI, Poole RL et al: Mutations in NLRP5 are associated with
reproductive wastage and multilocus imprinting disorders in humans. Nat Commun
2015; 6: 8086.
45 Tee L, Lim DH, Dias RP et al: Epimutation proﬁling in Beckwith–Wiedemann syndrome:
relationship with assisted reproductive technology. Clin Epigenet 2013; 5: 23.
46 Eggermann T, Schneider-Rätzke B, Begemann M, Spengler S: Isolated hypermethyla-
tion of GRB10 (7p12.2) in a Silver–Russell syndrome patient carrying a 20p13
microdeletion. Clin Genet 2014; 85: 399–400.
47 Keren B, Chantot-Bastaraud S, Brioude F et al: SNP arrays in Beckwith–Wiedemann
syndrome: an improved diagnostic strategy. Eur J Med Genet 2013; 56: 546–550.
48 Richards S, Aziz N, Bale S et al: Standards and guidelines for the interpretation of
sequence variants: a joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genet Med 2015; 17: 405–424.
49 Wallis Y, Payne S, McAnulty C et al: Practice Guidelines for the Evaluation of
Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics,
2013. Available from http://www.acgs.uk.com/media/774853/evaluation_and_
reporting_of_sequence_variants_bpgs_june_2013_-_ﬁnalpdf.pdf.
50 Niederhoffer KY, Penaherrera M, Pugash D et al: Beckwith–Wiedemann
syndrome in sibs discordant for IC2 methylation. Am J Med Genet A 2012; 158a:
1662–1669.
51 Kalish JM, Conlin LK, Bhatti TR et al: Clinical features of three girls with mosaic
genome-wide paternal uniparental isodisomy. Am J Med Genet A 2013; 161a:
1929–1939.
52 Behnecke A, Hinderhofer K, Jauch A, Janssen JW, Moog U: Silver–Russell syndrome
due to maternal uniparental disomy 7 and a familial reciprocal translocation t(7;13).
Clin Genet 2012; 82: 494–498.
53 Dupont JM, Cuisset L, Cartigny M et al: Familial reciprocal translocation t(7;16)
associated with maternal uniparental disomy 7 in a Silver–Russell patient. Am J Med
Genet 2002; 111: 405–408.
54 Alders M, Maas SM, Kadouch DJ et al: Methylation analysis in tongue tissue of BWS
patients identiﬁes the (EPI)genetic cause in 3 patients with normal methylation levels
in blood. Eur J Med Genet 2014; 57: 293–297.
55 Eggermann T, Brioude F, Russo S et al: Prenatal molecular testing for Beckwith–
Wiedemann and Silver–Russell syndromes: a challenge for molecular analysis and
genetic counseling. Eur J Hum Genet 2016; 24: 784–793.
56 Eggermann T, Buiting K, Temple IK: Clinical utility gene card for: Silver–Russell
syndrome. Eur J Hum Genet 2011; e-pub ahead of print 8 December 2010;
doi:10.1038/ejhg.2010.202.
This work is licensed under a Creative Com
mons Attribution-NonCommercial-ShareAlike 4.0
International License. The images or other third party material
in this article are included in the article’s Creative Commons
license, unless indicated otherwise in the credit line; if thematerial
is not included under the Creative Commons license, users will
need to obtain permission from the license holder to reproduce
the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
Molecular genetic testing for 11p15 imprinting disorders
K Eggermann et al
1387
European Journal of Human Genetics
